These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1230 related items for PubMed ID: 19487905

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
    Bánhegyi D, Katlama C, da Cunha CA, Schneider S, Rachlis A, Workman C, De Meyer S, Vandevoorde A, Van De Casteele T, Tomaka F.
    Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 11. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
    Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ.
    AIDS Res Hum Retroviruses; 2007 Dec 31; 23(12):1505-14. PubMed ID: 18160008
    [Abstract] [Full Text] [Related]

  • 12. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, CASTLE Study Team.
    Lancet; 2008 Aug 23; 372(9639):646-55. PubMed ID: 18722869
    [Abstract] [Full Text] [Related]

  • 13. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov 23; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 14. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.
    HIV Clin Trials; 2011 Nov 23; 12(5):255-67. PubMed ID: 22180523
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.
    Pharmacoeconomics; 2010 Nov 23; 28 Suppl 1():147-67. PubMed ID: 21182349
    [Abstract] [Full Text] [Related]

  • 16. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.
    AIDS; 2010 Jan 16; 24(2):223-30. PubMed ID: 20010070
    [Abstract] [Full Text] [Related]

  • 17. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
    González-García J, Cohen D, Johnson M, Sloan L, Fredrick L, Naylor C, da Silva B, Bernstein B, M05-730 Study Group.
    AIDS Res Hum Retroviruses; 2010 Aug 16; 26(8):841-5. PubMed ID: 20672994
    [Abstract] [Full Text] [Related]

  • 18. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.
    HIV Med; 2013 Aug 16; 14(7):437-44. PubMed ID: 23480640
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
    Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S.
    AIDS; 2009 Sep 24; 23(15):2005-13. PubMed ID: 19724191
    [Abstract] [Full Text] [Related]

  • 20. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B.
    HIV Clin Trials; 2007 Sep 24; 8(4):193-204. PubMed ID: 17720659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.